Conclusions: It is possible to run a homograft valve bank with minimum costs.

Cyclosporine increased homograft valve survival in animals, but has not been studied in humans.

The dynamic analysis evaluated the function of the aortic autograft and the pulmonary homograft.

We could not identify predictors for combined homograft dysfunction.

We present our experience with homograft valve banking with antibiotic and cryopreserved homografts spread over a quarter century.

A smaller diameter of the pulmonary homograft and severe pre-surgical PR were related to early homograft dysfunction after surgery.

Rapid degeneration of the pulmonary homograft and the propensity towards progressive dilatation of the neo-aorta are important postoperative considerations.

A porcine-valved Dacron conduit was used in 730, homograft in 239, and non-valved conduit in 126.

Overall freedom from significant homograft dysfunction was 66% after 5 years and 47% after 10 years.

Although cyclosporine failed to show a significant difference in signs of homograft degeneration, it might decrease the need for reoperation following the Ross procedure.

In 8 cases of NVE and 2 cases of PVE fresh, antibiotic sterilized aortic homograft was used to replace the aortic valve.

Due to limited availability of pulmonary homograft, we devised a novel technique for right ventricular outflow tract (RVOT) reconstruction by preparing indigenous Dacron valved conduit.

Methods: The cohort includes 112 patients who underwent aortic valve replacement with an aortic homograft for AIE between January 1990 and December 2014.

The freedom from reoperation for those who had an aortic homograft was 4 years and for those who had a pulmonary homograft was 3 years.

All patients underwent in situ repair with aortic homografts.

The concept that homografts are the valve substitute of choice in endocarditis cases cannot be supported by this study.